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The  efﬁcacy  of  a single  oral  treatment  with  sarolaner  (SimparicaTM, Zoetis),  a novel  isoxazoline  compound,
was  evaluated  against  ﬁve  tick  species  known  to  infest  dogs  in  the  United  States.  A  total  of  10 laboratory
studies,  two  against  each  species,  were  conducted  using  adult  purpose-bred  mongrels  or Beagle  dogs.  In
each study,  16  dogs  were  randomly  allocated  to one  of  two  treatment  groups  based  on  pre-treatment  host-
suitability  tick  counts.  Dogs  were  infested  with  approximately  50 unfed  adult  Amblyomma  americanum,
Amblyomma  maculatum,  Dermacentor  variabilis,  Ixodes  scapularis  or Rhipicephalus  sanguineus  ticks  on
Days  -2, 5,  12,  19,  26  and 33. On  Day 0,  dogs  were  treated  with  a placebo  or a sarolaner  tablet  providing
a  minimum  dose  of  2 mg/kg.  Tick  counts  were  conducted  48  h after  treatment  and  after  each  subsequent
weekly  re-infestation.
There  were  no  treatment-related  adverse  reactions  during  any  of  the  studies.  Dogs  in  the  placebo-
treated  group  maintained  tick  infestations  throughout  the studies.  Geometric  mean  live  tick  counts  were
signiﬁcantly  lower  (P≤0.0001)  in the  sarolaner-treated  group  compared  to  the  tick counts  in  the  placebo
group  at  all  timepoints.  Treatment  with  sarolaner  resulted  in  ≥99.6%  efﬁcacy  against  existing  infestations
of all  ﬁve  tick  species  within  48  h. The  efﬁcacy  against  weekly  post-treatment  re-infestations  of all  tick
species  was  ≥96.9%  for at least  35  days  after  treatment.Thus,  a single  dose  of  sarolaner  administered  orally  at the  minimum  dosage  of  2 mg/kg,  resulted  in
excellent  efﬁcacy  within  48 h against  existing  tick  infestations,  and  against  weekly  re-infestations  for
35  days  after  treatment.  These  studies  conﬁrmed  that  administration  of the  minimum  dose  of  sarolaner
will provide  rapid  treatment  of  existing  infestations  and  give  at least  one  month  of  control  against  re-
infestation  by the common  tick  species  affecting  dogs  in  the  US.
© 2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Ticks are recognized as one of the most prevalent ectoparasites
n domestic animals. In addition to the local irritation resulting
rom the bite, ticks may  also directly injure animals by produc-
ng generalized hypersensitivity reactions, and by causing tick
aralysis resulting from a toxin produced by the salivary glands
Muller and Kirk, 2013). Ticks are also the vectors of many zoonotic
iseases in the United States including Lyme disease (caused by
orrelia burgdorferi), which is transmitted by Ixodes spp. and Rocky
∗ Corresponding author.
E-mail address: robert.six@Zoetis.com (R.H. Six).
ttp://dx.doi.org/10.1016/j.vetpar.2015.12.023
304-4017/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Mountain spotted fever (caused by Rickettsia rickettsia) which is
transmitted by Dermacentor spp. Other tick-borne pathogens cause
dog-speciﬁc infections, such as Babesia canis which is primar-
ily transmitted by Dermacentor reticulatus,  and Babesia vogeli and
Ehrlichia canis, which are primarily transmitted by Rhipicephalus
sanguineus (Chomel, 2011; Dantas-Torres et al., 2012).
Tick paralysis toxins and tick-borne pathogens can cause sub-
clinical to life threatening diseases in dogs and humans (Blagburn
and Dryden, 2009). Recently, possibly due to changes in awareness,
climate and or lifestyle, the incidence of tick-borne diseases has
been rising markedly (Blagburn and Dryden, 2009; Jaenson et al.,
2012; Lindgren et al., 2000; Chomel, 2011).
Tick prevention and control programs for companion animals
were originally based on the topical application of acaricides. The
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ost widely used products are generally applied as spot-on appli-
ations on a monthly schedule or as collars and may  include
ompounds with efﬁcacy against both ﬂeas and ticks. A number of
hemical classes are used for tick control and include: phenyl pyra-
oles e.g., ﬁpronil; pyrethroids e.g., permethrin and deltamethrin;
nd octopamines e.g., amitraz (Rust, 2005). Programs to prevent the
ransmission of tick-borne pathogens to dogs have largely relied on
outine use of these types of products coupled with other means of
ector avoidance.
Recently, a new class of compounds, the isoxazolines, have
hown excellent efﬁcacy following oral administration against
eas, along with enhanced efﬁcacy against ticks (Rohdich et al.,
014; Shoop et al., 2014). High efﬁcacy via oral administration is
ikely to increase compliance from pet owners by eliminating the
ifﬁculties of administering topical products, and removing the
eed to temporarily isolate the treated-pet from children and other
ets required with some topical products where contact must be
voided until the product is dry. Sarolaner (SimparicaTM, Zoetis) is
 novel isoxazoline with potent systemic activity against ticks and
eas after oral administration that was developed speciﬁcally for
se in dogs (McTier et al., 2016a) and has demonstrated month long
fﬁcacy against ticks after a single oral dose (McTier et al., 2016b).
Here we report laboratory studies conducted to conﬁrm the
fﬁcacy of sarolaner, at a single oral dose of 2 mg/kg, against exist-
ng infestations and subsequent weekly re-infestations of ﬁve tick
pecies commonly infesting dogs in the US for up to ﬁve weeks after
reatment.
. Materials and methods
Two studies were conducted to conﬁrm the efﬁcacy of sarolaner
gainst each of the following tick species commonly infesting
ogs in the United States: Amblyomma americanum (Lone Star
ick); Amblyomma maculatum (Gulf Coast tick); Dermacentor vari-
bilis (American dog tick); R. sanguineus (brown dog tick); and
xodes scapularis (black legged tick). The studies were conducted
t research laboratories in Arkansas (AR), Texas (TX) and Cali-
ornia (CA). All studies were conducted in accordance with the
orld Association for the Advancement of Veterinary Parasitology
WAAVP) guidelines for evaluating the efﬁcacy of parasiticides for
he treatment, prevention and control of ﬂea and tick infestation
n dogs and cats (Marchiondo et al. 2013) and complied with Good
linical Practices, (EMEA, 2000). Study protocols were reviewed
nd approved by the local and/or Zoetis Institutional Animal Care
nd Use Committee.
.1. Animals
All dogs used in these studies had not been treated with an
ctoparasiticide for at least 60 days and demonstrated good tick
etention prior to treatment, and were in good health at enrollment.
ixteen purpose-bred dogs, including both sexes, were enrolled in
ach study. Dogs were Beagles or mixed-breed, ranging in age from
 months to 13 years, and weighing between 5.6 kg and 35.0 kg.
emale dogs were conﬁrmed not to be pregnant or lactating. Each
og was individually identiﬁed by a unique and permanent code
microchip or tattoo). Dogs were housed in individual indoor pens
uch that no physical contact was possible between them, and the
ossibility of tick transfer among animals was minimal. Dogs were
ed an appropriate maintenance ration of a commercial canine diet
or the duration of the study. Water was available ad libitum..2. Experimental design and methods
Day 0 for each study was the day dogs were administered the
tudy treatment. Dogs were acclimated to the study conditions fortology 222 (2016) 28–32 29
at least 7 days prior to treatment. The dogs were observed for gen-
eral health at least once daily throughout the studies. A physical
exam was performed on each dog by a veterinarian to determine
health and suitability prior to inclusion in the trial. For tick infes-
tations, a pre-counted aliquot of approximately 50 (1:1 sex ratio)
adult unfed ticks were placed onto the hair coat and allowed to dis-
perse on the dog. At the California and Arkansas sites, dogs were
placed in travel crates for 2–4 h after infestation to restrict the dogs’
movement and facilitate tick (A. americanum, A. maculatum, D. vari-
abilis, R. sanguineus) attachment. For A. americanum infestations at
the California facility, the dogs were also lightly sedated prior to
infestation to further enhance attachment for this species.
Tick counts were performed by personnel trained in the stan-
dard procedures in use at the test facility. Personnel changed pro-
tective clothing between dogs to avoid any cross-contamination,
and personnel conducting parasite or other observations were
unaware of treatment assignments. Initially, the entire dog’s entire
body was  examined, pushing the hair against its natural nap, expos-
ing, counting and removing the ticks. After the manual inspection,
an extra-ﬁne tooth comb was  used to comb the animal to remove
any missed ticks. Each dog was examined for at least 10 min. If ticks
were encountered in the last minute, combing was continued in one
minute increments until no ticks were encountered. The ticks were
examined to assess viability and the numbers of live and dead ticks
was quantiﬁed.
At least 16 animals arrived into the housing facilities on or before
Day-11. General health observations were performed at least once
a day from the start of the acclimation period. All dogs were given a
physical examination to evaluate general health and suitability for
inclusion into the study. The dogs were examined to ensure they
were free of ticks and were then infested to determine the host suit-
ability between Day-11 and Day-7. The live attached ticks present
on each dog were counted and removed at 48 (±2) hours after infes-
tation. When more than 16 dogs were available, those with the
highest counts were selected for inclusion. Dogs were ranked by
decreasing tick count into blocks of two and randomly allocated
within block to treatment with placebo or sarolaner tablets. Blocks
of dogs were randomly assigned to adjacent pens within the test
facility. Dogs were moved into their allocated pens on or before
Day-2.
Dogs were weighed and infested with ticks on Day-2. On Day
0, the dogs were dosed orally with one to three tablets (placebo or
sarolaner strengths of 5, 10, 20, or 40 mg)  such that the sarolaner
dose was as close as possible to 2 mg/kg without under-dosing.
Each dog was offered its regular food ration ∼20 min before dos-
ing. Dogs were hand-pilled to ensure accurate dose delivery. Each
dog was  observed for several minutes after dosing for evidence that
the dose was swallowed, and for potential adverse events associ-
ated with treatment and then for up to 2 h for any signs of emesis.
Dogs were observed for general health and any reaction to treat-
ment approximately 1, 3 and 6 h after treatment. On Day  2, each
dog was examined to remove and count ticks. Subsequently, all
animals were re-infested with ticks on Days 5, 12, 19, 26 and 33.
All dogs were examined, combed and parasite counted on Days 7,
14, 21, 28 and 35. Ticks exhibiting movement after gentle touching
or exposure to CO2 were considered alive.
2.3. Parasites
Ticks of each species were obtained from four different labora-
tory maintained colonies (Tables 1–5 ). These ticks were originally
isolated from the ﬁeld and had wild caught ticks introduced into
each tick colony every 1–2 years or generations. One  I. scapularis
study (TX) utilized wild caught adult ticks from South Carolina.
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Table  1
Geometric (arithmetic) mean live Amblyomma americanum (lone star tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls
for  dogs treated once orally with sarolaner chewable tablets at 2 mg/kg in two laboratory studies.
Laboratory/tick strain Day Placebo Sarolaner % Efﬁcacyb
Mean Range Mean Range
California/Stillwater,
OK
2 23.3 (23.8) 16–30 0.0a (0.0) 0–0 100
7  19.2 (20.8) 9–32 0.2a(0.3) 0–1 99.0 (98.8)
14  15.6 (20.8) 1–32 0.0a (0.0) 0–0 100
21  22.3 (24.0) 9–38 0.1a (0.1) 0–1 99.6 (99.5)
28  26.1 (28.0) 12–42 0.0a(0.0) 0–0 100
35  24.7 (25.1) 13–33 0.8a (1.4) 0–5 96.9 (94.5)
Arkansas/College
station, TX
2 23.7 (26.3) 6–39 0.1a (0.1) 0–1 99.6 (99.5)
7  14.3 (15.0) 7–19 0.0a(0.0) 0–0 100
14 18.8 (19.1) 13–23 0.0a (0.0) 0–0 100
21  13.2 (14.3) 4–20 0.0a (0.0) 0–0 100
28  17.3 (18.0) 9–25 0.0a (0.0) 0–0 100
35  15.1 (15.4) 11–21 0.0a (0.0) 0–0 100
a Geometric mean live tick count signiﬁcantly lower than placebo (P≤0.0001).
b Efﬁcacy calculated using arithmetic mean live tick counts is shown in parenthesis.
Table 2
Geometric (arithmetic) mean live Amblyomma maculatum (gulf coast tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls
for  dogs treated once orally with sarolaner chewable tablets at 2 mg/kg in two laboratory studies.
Laboratory/tick strain Day Placebo Sarolaner % Efﬁcacyb
Mean Range Mean Range
Arkansas/College
station, TX
2 30.1 (32.3) 12–48 0.0a (0.0) 0–0 100
7  31.1 (34.6) 8–50 0.0a (0.0) 0–0 100
14  26.6 (28.4) 15–47 0.1a (0.1) 0–1 99.7 (99.6)
21  25.8 (27.5) 17–50 0.0a (0.0) 0–0 100
28  28.0 (29.5) 18–50 0.0a (0.0) 0–0 100
35  20.6 (22.4) 8–35 0.0a (0.0) 0–0 100
Texas/Stillwater, OK 2 21.5 (25.8) 6–46 0.0a (0.0) 0–0 100
7  25.0 (28.3) 8–48 0.0a (0.0) 0–0 100
14  32.5 (34.5) 15–60 0.1a (0.3) 0–2 99.5 (99.3)
21  28.6 (29.6) 15–40 0.0a(0.0) 0–0 100
28  30.6 (32.4) 17–51 0.1a (0.3) 0–2 99.5 (99.2)
35  26.1 (29.0) 10–48 0.2a (0.3) 0–1 99.3 (99.1)
a Geometric mean live tick count signiﬁcantly lower than placebo (P<0.0001).
b Efﬁcacy calculated using arithmetic mean live tick counts is shown in parenthesis.
Table 3
Geometric (arithmetic) mean live Dermacentor variabilis (American dog tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls
for  dogs treated once orally with sarolaner chewable tablets at 2 mg/kg in two laboratory studies.
Laboratory/tick strain Day Placebo Sarolaner % Efﬁcacyb
Mean Range Mean Range
Arkansas/Greenbrier,
AR
2 21.3 (22.4) 15–35 0.0a (0.0) 0–0 100
7  18.6 (20.1) 10–38 0.1a(0.1) 0–1 99.5 (99.4)
14  20.8 (21.0) 15–26 0.1a(0.3) 0–2 99.3 (98.8)
21  15.6 (17.5) 5–33 0.0a(0.0) 0–0 100
28  16.2 (17.4) 10–31 0.0a (0.0) 0–0 100
35  17.9 (18.9) 8–25 0.0a (0.0) 0–0 100
California/Henderson,
NC
2  33.4 (35.5) 13–50 0.1a (0.1) 0–1 99.7 (99.6)
7  35.2 (36.0) 24–51 0.2a (0.3) 0–1 99.5 (99.3)
14  28.0 (29.9) 17–50 0.4a (0.5) 0–1 98.5 (98.3)
21  32.4 (34.6) 15–54 0.1a (0.1) 0–1 99.7 (99.6)
28  22.4 (23.5) 12–37 0.2a (0.3) 0–1 99.2 (98.9)
35  22.6 (24.9) 11–53 0.1a (0.3) 0–2 99.3 (99.0)
a
b .
2
e
l
t
d
a
eGeometric mean live tick count signiﬁcantly lower than placebo (P<0.0001).
Efﬁcacy calculated using arithmetic mean live tick counts is shown in parenthesis
.4. Data analysis
The individual dog was the experimental unit and the primary
ndpoint was live tick counts. Tick counts were transformed by the
og e(count + 1) transformation prior to analysis in order to stabilize
he variance and normalize the data. Using the PROC MIXED proce-
ure (SAS 9.2, Cary NC), transformed counts were analyzed using
 mixed linear model by timepoint. The model included the ﬁxed
ffect of treatment. The random effects included block and error.Testing was  two-sided at the signiﬁcance level  ˛ = 0.05. Percent
efﬁcacy was calculated using Abbott’s formula:
(Mean placebo − mean treated)
%Efﬁcacy =
Mean placebo
× 100
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Table  4
Geometric (arithmetic) mean live Ixodes scapularis (black legged tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls for dogs
treated once orally with sarolaner chewable tablets at 2 mg/kg in two  laboratory studies.
Laboratory/tick strain Day Placebo Sarolaner % Efﬁcacy
Mean Range Mean Range
Arkansas/Stillwater, OK 2 24.7 (25.3) 17–35 0.0a (0.0) 0–0 100
7  28.4 (28.9) 20–35 0.0a (0.0) 0–0 100
14  24.8 (25.1) 18–30 0.0a (0.0) 0–0 100
21  17.4 (20.5) 3–30 0.0* (0.0) 0–0 100
28  20.9 (22.4) 11–38 0.0a (0.0) 0–0 100
35  25.8 (27.3) 10–36 0.0a(0.0) 0–0 100
Texas/SC wild caught
adults
2 14.7 (15.1) 8–21 0.0 (0.0) 0–0 100
7  8.6 (10.8) 2–19 0.0a(0.0) 0–0 100
14  15.3 (16.3) 7–28 0.0a (0.0) 0–0 100
21 10.7 (12.1) 3–21 0.0a(0.0) 0–0 100
28  10.8 (11.5) 5–18 0.0a (0.0) 0–0 100
35  15.5 (16.1) 10–25 0.0a (0.0) 0–0 100
a Geometric mean live tick count signiﬁcantly lower than placebo (P<0.0001).
Table 5
Geometric (arithmetic) mean live Rhipicephalus sanguineus (brown dog tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls
for  dogs treated once orally with sarolaner chewable tablets at 2 mg/kg in two  laboratory studies.
Laboratory/tick strain Day Placebo Sarolaner % Efﬁcacyb
Mean Range Mean Range
California/Henderson,
NC
2 32.7 (34.5) 14–52 0.0a(0.0) 0–0 100
7  30.4 (31.1) 22–47 0.1a (0.1) 0–1 99.7 (99.6)
14  26.9 (27.5) 18–35 0.0a (0.0) 0–0 100
21  27.9 (29.8) 14–51 0.0a (0.0) 0–0 100
28  24.2 (26.1) 11–36 0.1a (0.1) 0–1 99.6 (99.5)
35  26.1 (27.0) 15–33 0.8a (0.9) 0–2 97.1 (96.8)
Arkansas/Greenbrier,
AR
2  24.3 (25.5) 15–36 0.0a (0.0) 0–0 100
7  17.9 (18.4) 13–26 0.0a (0.0) 0–0 100
14  18.0 (19.8) 7–34 0.0a (0.0) 0–0 100
21  19.0 (20.6) 8–31 0.0a (0.0) 0–0 100
28  19.1 (20.6) 10–33 0.0a(0.0) 0–0 100
35  20.7 (22.0) 13–36 0.0a (0.0) 0–0 100
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aa Geometric mean live tick count signiﬁcantly lower than placebo (P<0.0001).
b Efﬁcacy calculated using arithmetic mean live tick counts is shown in parenthe
. Results
.1. Efﬁcacy
Dogs in the placebo-treated groups generally maintained tick
nfestations throughout the studies (Tables 1–5). Mean tick recov-
ry from the placebo dogs ranged from about 25–70% of the applied
nfestation. The use of sedation of the dogs for tick infestation (at
he CA site) appeared to improve tick recovery rates for A. amer-
canum (Table 1). However, there was variation in tick retention
mong study sites and tick strains that was most obvious when
ild caught versus colony-reared I. scapularis were used (Table 4).
For A. americanum, efﬁcacy against existing infestations was 100
nd 99.6% at 48 h after treatment in the two studies. For subse-
uent weekly re-infestations, efﬁcacy was ≥96.9% in the CA study
nd 100% in the AR study through 35 days post treatment (Table 1).
fﬁcacy against existing infestations of A. maculatum was 100% at
8 h after treatment in both studies, and efﬁcacy against subse-
uent weekly re-infestations was ≥99.3% in the TX study and ≥99.7
n the AR study through 35 days post treatment (Table 2). Efﬁcacy
gainst existing D. variabilis infestations was 100 and 99.7% at 48 h
fter treatment. Following weekly re-infestations, efﬁcacy against
his tick was ≥98.5% in the CA study and ≥99.3 in the AR study
hrough 35 days post treatment (Table 3). For I. scapularis, efﬁcacy
as 100% against existing infestations at 48 h after treatment and
t 48 h after subsequent weekly re-infestations for 35 days in both
tudies (Table 4). In the AR study with R. sanguineus,  efﬁcacy was
00% against the existing infestation at 48 h after treatment and
t 48 h after subsequent weekly re-infestations through 35 dayspost treatment (Table 5). In the CA R. sanguineus study, efﬁcacy
was 100% at 48 h after treatment and efﬁcacy against subsequent
weekly re-infestations was  ≥97.1% for 35 days post treatment. For
all tick species, the mean tick counts for sarolaner-treated dogs
were signiﬁcantly lower than those for placebo-treated dogs at all
post treatment counts (P ≤ 0.0001)
3.2. Health observations
No adverse events related to treatment with sarolaner were
reported in any study.
4. Discussion
Until recently there were no orally administered marketed
products that could quickly kill ticks and also provide a high level of
residual efﬁcacy for at least a month or longer. With the introduc-
tion of the isoxazolines, pet owners and veterinarians now have a
highly effective alternative to topical spot-on formulations for the
control of ﬂeas and ticks on dogs.
The dose of sarolaner was  selected to provide immediate treat-
ment of existing infestations and one month’s consistent control
of new infestations of the least sensitive tick commonly found on
dogs (A. maculatum, McTier et al., 2016b). Thus, it was expected
that a single oral dose of sarolaner at the minimum dose of 2 mg/kg
would provide robust efﬁcacy against the main ticks infesting dogs
in the US for at least a month.
The 10 studies reported here conﬁrmed the consistent, high efﬁ-
cacy of sarolaner against the most common ticks found on dogs in
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he US for 35 days. A single oral dose of sarolaner at 2 mg/kg pro-
ided 100% efﬁcacy against existing infestations of I. scapularis,  R.
anguineus and A. maculatum, and ≥99.6% efﬁcacy against A. amer-
canum and D. variabilis within 48 h of dosing. Following weekly
e-infestations of all ﬁve species, the single treatment resulted in
igniﬁcant and ≥96.9% reductions in live ticks for 35 days.
An initial attachment and feeding of at least 24–48 h is required
efore transmission of most tick-borne pathogens can occur (Little,
007; Salinas et al., 2010). If the infected ticks are killed within that
ime period, the transmission may  be prevented (Wengenmayer
t al., 2014). In the studies presented here, on all but three of the
fty post treatment tick evaluations for all species, the efﬁcacy
as ≥99%. This consistent high level of efﬁcacy against the com-
on  tick species suggests that monthly treatment with sarolaner
hould reduce the risk of transmission of tick-borne diseases, which
s important given that the incidence and spread of tick-borne
iseases has been rising markedly (Blagburn and Dryden, 2009;
indgren et al., 2000; Chomel, 2011; Jaenson et al., 2012).
. Conclusions
The robust and consistent efﬁcacy of a single oral treatment
f sarolaner at the minimum dose of 2.0 mg/kg against the ﬁve
ajor US tick species was conﬁrmed against existing infestations
nd weekly re-infestations for 5 weeks. Efﬁcacy of ≥99.6% was
chieved versus existing infestations within 48 h after treatment.
fﬁcacy was maintained at greater than 96.9% within 48 h after
e-infestation for the 35 day duration of all studies.
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